Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May 1.
doi: 10.1002/jmv.25961. Online ahead of print.

Convalescent Plasma Transfusion for the Treatment of COVID-19: Systematic Review

Affiliations
Review

Convalescent Plasma Transfusion for the Treatment of COVID-19: Systematic Review

Karthick Rajendran et al. J Med Virol. .

Abstract

The recent emergence of coronavirus disease 2019 (COVID-19) pandemic has reassessed the usefulness of historic convalescent plasma transfusion (CPT). This review was conducted to evaluate the effectiveness of CPT therapy in COVID-19 patients based on the publications reported till date. To our knowledge, this is the first systematic review on convalescent plasma on clinically relevant outcomes in individuals with COVID-19. PubMed, EMBASE, and Medline databases were searched upto 19 April 2020. All records were screened as per the protocol eligibility criteria. We included five studies reporting CPT to COVID-19 patients. The main findings from available data are as follows: (a) Convalescent plasma may reduce mortality in critically ill patients, (b) Increase in neutralizing antibody titers and disappearance of SARS-CoV-2 RNA was observed in almost all the patients after CPT therapy, and (c) Beneficial effect on clinical symptoms after administration of convalescent plasma. Based on the limited scientific data, CPT therapy in COVID-19 patients appears safe, clinically effective, and reduces mortality. Well-designed large multicenter clinical trial studies should be conducted urgently to establish the efficacy of CPT to COVID-19 patients.

Keywords: COVID-19; SARS-CoV-2; convalescent plasma transfusion (CPT); neutralizing antibody.

Similar articles

See all similar articles

References

REFERENCES

    1. World Health Organization. Coronavirus disease 2019 (COVID-19) - Situation Repor - 90 (April 19, 2020). https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Accessed April 19, 2020.
    1. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance 13 March 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed April 18, 2020.
    1. Casadevall Arturo, Pirofski Liise-anne. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548.
    1. Food and Drug Administration. Recommendations for Investigational COVID-19 Convalescent Plasma, Content current as of: 04/13/2020. https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/recommendations-investigational-covid-19-convalescent-plasma. Accessed April 18, 2020.
    1. Moher David, Shamseer Larissa, Clarke Mike, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.

LinkOut - more resources

Feedback